Efficacy of lazertinib for symptomatic or asymptomatic brain metastases in treatment‐naive patients with advanced EGFR mutation‐positive non‐small cell lung cancer: Protocol of an open‐label, single‐arm phase II trial

Abstract Introduction Non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation has a higher incidence of brain metastases than wild‐type EGFR mutations. Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor (TKI), targets both EGFR‐TKI sensitizing and T790M‐r...

詳細記述

書誌詳細

出版年:	Thoracic Cancer
主要な著者:	Bora Lee, Wonjun Ji, Jae Cheol Lee, Si Yeol Song, Young Seob Shin, Young Hyun Cho, Ji Eun Park, Hyungjun Park, Chang‐Min Choi
フォーマット:	論文
言語:	英語
出版事項:	Wiley 2023-08-01
主題:	brain metastases epidermal growth factor receptor lazertinib non‐small cell lung cancer
オンライン･アクセス:	https://doi.org/10.1111/1759-7714.15018